<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ketendo</journal-id><journal-title-group><journal-title xml:lang="ru">Клиническая и экспериментальная тиреоидология</journal-title><trans-title-group xml:lang="en"><trans-title>Clinical and experimental thyroidology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-5472</issn><issn pub-type="epub">2310-3787</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/ket12828</article-id><article-id custom-type="elpub" pub-id-type="custom">ketendo-12828</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальное исследование</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original studies</subject></subj-group></article-categories><title-group><article-title>Применимость текстурных признаков ОФЭКТ/КТ в оценке ответа дифференцированного рака щитовидной железы на радиойодтерапию</article-title><trans-title-group xml:lang="en"><trans-title>SPECT/CT textural features applicability in differentiated thyroid cancer response assessment after radioiodine therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-2420-4650</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мальцев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Maltsev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мальцев Михаил Сергеевич</p><p>Москва</p></bio><bio xml:lang="en"><p>Mikhail S. Maltsev</p><p> Moscow</p></bio><email xlink:type="simple">misha.malcev.01@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-1632-2197</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рейнберг</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Reinberg</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рейнберг Мария Валентиновна</p><p>Москва</p></bio><bio xml:lang="en"><p>Marie V. Reinberg,  MD</p><p> Moscow</p></bio><email xlink:type="simple">mrezerford12@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5592-4727</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трухин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Trukhin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Трухин Алексей Андреевич, к.т.н.</p><p>Москва,117292, ул. Дм. Ульянова, д. 11</p><p> </p></bio><bio xml:lang="en"><p>Alexey A. Trukhin, PhD</p><p>Moscow, 11, Dm. Ulyanov St., 11,  117292</p></bio><email xlink:type="simple">Alexey.trukhin12@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-0327-4135</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алиева</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Alieva</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алиева Сэма Ильгаровна, ординатор</p><p>Москва</p></bio><bio xml:lang="en"><p>Sema I. Alieva, resident</p><p> Moscow</p></bio><email xlink:type="simple">sema_alieva2902@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-8035-676X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Манаев</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Manaev</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Манаев Алмаз Вадимович</p><p>Москва</p></bio><bio xml:lang="en"><p>Almaz V. Manaev</p><p> Moscow</p></bio><email xlink:type="simple">a.manaew2016@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2326-1396</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Серженко</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Serzhenko</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Серженко Сергей Сергеевич</p><p>Москва</p></bio><bio xml:lang="en"><p>Sergey S. Serzhenko, MD</p><p> Moscow</p></bio><email xlink:type="simple">vv1ld@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3220-2438</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слащук</surname><given-names>К. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Slashchuk</surname><given-names>K. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Слащук Константин Юрьевич, к.м.н.</p><p>Москва</p></bio><bio xml:lang="en"><p>Konstantin Yu. Slashchuk, MD, PhD</p><p> Moscow</p></bio><email xlink:type="simple">slashuk911@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный исследовательский ядерный институт «МИФИ»; Московский многопрофильный клинический центр «Коммунарка»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Nuclear Institute «MEPhI»; Moscow Multidisciplinary Clinical Center «Kommunarka»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр им. академика И.И. Дедова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Национальный исследовательский ядерный институт «МИФИ»; Национальный медицинский исследовательский центр им. академика И.И. Дедова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Nuclear Institute «MEPhI»; Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>09</month><year>2025</year></pub-date><volume>21</volume><issue>1</issue><fpage>4</fpage><lpage>14</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мальцев М.С., Рейнберг М.В., Трухин А.А., Алиева С.И., Манаев А.В., Серженко С.С., Слащук К.Ю., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Мальцев М.С., Рейнберг М.В., Трухин А.А., Алиева С.И., Манаев А.В., Серженко С.С., Слащук К.Ю.</copyright-holder><copyright-holder xml:lang="en">Maltsev M.S., Reinberg M.V., Trukhin A.A., Alieva S.I., Manaev A.V., Serzhenko S.S., Slashchuk K.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cet-endojournals.ru/jour/article/view/12828">https://www.cet-endojournals.ru/jour/article/view/12828</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Несмотря на широкое развитие методов анализа медицинских изображений, включая технологии радиомики, их внедрение в повседневную клиническую практику остаётся ограниченным. Одним из перспективных направлений является использование текстурных признаков, рассчитываемых по данным гибридных методов визуализации, таких как однофотонная эмиссионная компьютерная томография, совмещённая с компьютерной томографией (ОФЭКТ/КТ). Эти признаки отражают пространственные особенности распределения радиофармацевтических препаратов и могут быть использованы для прогнозирования ответа на лечение.</p></sec><sec><title>Цель</title><p>Цель. Оценить прогностическую ценность текстурных признаков, извлечённых из ОФЭКТ/КТ-изображений, в оценке ответа на радиойодтерапию (РЙТ) дифференцированного рака щитовидной железы (ДРЩЖ).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование были включены 53 пациента с ДРЩЖ, которым проводилась посттерапевтическая ОФЭКТ/КТ через 72 часа после введения I-131. В общей сложности было проанализировано 89 областей интереса, включая 88 зон остаточной ткани щитовидной железы (ЩЖ) и 61 метастатический очаг ДРЩЖ. Статус заболевания (ремиссия или рецидив) определяли через 6 месяцев после РЙТ в соответствии с клинико-лабораторными и инструментальными критериями. Для оценки прогностической ценности текстурных признаков использовались модели логистической регрессии и ROC-анализ. Признаки отбирались с использованием алгоритмов mRmR, Lasso и статистических критериев.</p></sec><sec><title>Результаты</title><p>Результаты. Созданы и протестированы диагностические модели, основанные на текстурных признаках, отдельно для остаточной ткани ЩЖ и метастатических очагов ДРЩЖ. Модель, построенная на признаках метастазов ДРЩЖ, продемонстрировала высокую прогностическую ценность (AUC = 0,88), в то время как модель, построенная на данных остаточной ткани ЩЖ, показала умеренную прогностическую ценность (AUC = 0,61).</p></sec><sec><title>Заключение</title><p>Заключение. Текущее исследование демонстрирует возможность применения радиомики, основанной на выделении текстурных признаков накопления I-131 на изображения ОФЭКТ/КТ для прогнозирования исходов радиойодтерапии при ДРЩЖ. Использование этих признаков может повысить точность стратификации риска рецидива и персонализировать РЙТ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: Despite the significant advancement of medical image analysis methods, including radiomics technologies, their routine integration into clinical practice remains limited. One promising direction is the use of textural features derived from hybrid imaging modalities, such as single-photon emission computed tomography combined with computed tomography (SPECT/CT). These features reflect the spatial characteristics of radiopharmaceutical distribution and can potentially be used to predict treatment response.</p></sec><sec><title>OBJECTIVE</title><p>OBJECTIVE: Assess the prognostic value of textural features extracted from post-therapeutic SPECT/CT images in evaluating the response to radioiodine therapy (RIT) in patients with differentiated thyroid cancer (DTC).</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: The study included 53 patients with DTC who underwent post-therapeutic SPECT/CT imaging 72 hours after administration of sodium iodine I-131. A total of 88 accumulation areas in the residual thyroid gland (thyroid gland) tissue and 61 metastatic foci of prostate cancer were analyzed. Disease status (remission or recurrence) was assessed six months after RIT based on clinical, laboratory, and imaging criteria. Logistic regression models and receiver operating characteristic (ROC) analysis were used to evaluate the predictive value of the extracted textural features. Feature selection was performed using mRmR, Lasso, and conventional statistical criteria.</p></sec><sec><title>RESULTS</title><p>RESULTS: Diagnostic models based on textural features were developed and tested separately for residual thyroid tissue and metastatic DTC lesions. The model based on features from metastatic lesions demonstrated high predictive performance (AUC = 0.88), while the model based on residual thyroid tissue showed moderate prognostic value (AUC=0.61).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: This study demonstrates the feasibility of using radiomics based on SPECT/CT-derived I-131 uptake textural features to predict outcomes of radioiodine therapy in DTC. The application of these features may enhance the accuracy of recurrence risk stratification and contribute to more personalized treatment strategies</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>прогнозирование</kwd><kwd>дифференцированный рак щитовидной железы</kwd><kwd>радиойодтерапия</kwd><kwd>текстурные признаки</kwd><kwd>ядерная медицина</kwd><kwd>персонализированная медицина</kwd><kwd>ОФЭКТ/КТ</kwd><kwd>радиомика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>prognosis</kwd><kwd>differentiated thyroid cancer</kwd><kwd>radioiodine therapy</kwd><kwd>textural features</kwd><kwd>nuclear medicine</kwd><kwd>personalized medicine</kwd><kwd>SPECT/CT</kwd><kwd>radiomics</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в соответствии с планом государственного задания. Регистрационный номер 123021000041-6.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Трухин А.А. Методы и средства повышения эффективности лечебно-диагностических процессов в аппаратно-программном комплексе радиойодтерапии тиреотоксикоза человека: Дис. … канд. тех. наук. — Москва, 2022.</mixed-citation><mixed-citation xml:lang="en">Trukhin A.A. Metody i sredstva povysheniya effektivnosti lechebno-diagnosticheskih processov v apparatno-programmnom komplekse radiojodterapii tireotoksikoza cheloveka: Dis. … kand. tekh. nauk. — Moskva, 2022.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Vučenović VT, Rajkovača Z, Jelić D., Stanimirović D., Vuleta G., Miljković B., Vučićević K. Investigation of factors influencing radioiodine 131I biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach 129 V. European journal of clinical pharmacology. 2018;74(8):1037– 1045.</mixed-citation><mixed-citation xml:lang="en">Vučenović VT, Rajkovača Z, Jelić D., Stanimirović D., Vuleta G., Miljković B., Vučićević K. Investigation of factors influencing radioiodine 131I biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach 129 V. European journal of clinical pharmacology. 2018;74(8):1037– 1045.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pecora А. Texture analysis in metastases of patients affected by metastatic differentiated thyroid carcinoma treated with 131I. 2019</mixed-citation><mixed-citation xml:lang="en">Pecora А. Texture analysis in metastases of patients affected by metastatic differentiated thyroid carcinoma treated with 131I. 2019</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vallières M, Kay-Rivest E, Perrin LJ, et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep. 2017. doi: https://doi.org/10.1038/s41598-017-10371-5</mixed-citation><mixed-citation xml:lang="en">Vallières M, Kay-Rivest E, Perrin LJ, et al. Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Sci Rep. 2017. doi: https://doi.org/10.1038/s41598-017-10371-5</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fornacon-Wood I, Mistry H, Ackermann CJ, Blackhall F, McPartlin A, et al. Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform. Eur Radiol. 2020;30(11):6241-6250. doi: https://doi.org/10.1007/s00330-020-06957-9</mixed-citation><mixed-citation xml:lang="en">Fornacon-Wood I, Mistry H, Ackermann CJ, Blackhall F, McPartlin A, et al. Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform. Eur Radiol. 2020;30(11):6241-6250. doi: https://doi.org/10.1007/s00330-020-06957-9</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Huang EP, O’Connor JPB, McShane LM, Giger ML, Lambin P, et al. Criteria for the translation of radiomics into clinically useful tests. Nat Rev Clin Oncol. 2023;20(2):69-82. doi: https://doi.org/10.1038/s41571-022-00707-0</mixed-citation><mixed-citation xml:lang="en">Huang EP, O’Connor JPB, McShane LM, Giger ML, Lambin P, et al. Criteria for the translation of radiomics into clinically useful tests. Nat Rev Clin Oncol. 2023;20(2):69-82. doi: https://doi.org/10.1038/s41571-022-00707-0</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zwanenburg A, et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020;295(2):328-338. doi: https://doi.org/10.1148/radiol.2020191145</mixed-citation><mixed-citation xml:lang="en">Zwanenburg A, et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020;295(2):328-338. doi: https://doi.org/10.1148/radiol.2020191145</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dewaraja Y, Sjögreen-gleisner K. Dosimetry for Radiopharmaceutical Therapy, Non-serial Publications , IAEA, Vienna 2024. doi:https://doi.org/10.61092/iaea.xlzb-6h67</mixed-citation><mixed-citation xml:lang="en">Dewaraja Y, Sjögreen-gleisner K. Dosimetry for Radiopharmaceutical Therapy, Non-serial Publications , IAEA, Vienna 2024. doi:https://doi.org/10.61092/iaea.xlzb-6h67</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Durante C. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy, 2006, doi: https://doi.org/10.1210/jc.2005-2838</mixed-citation><mixed-citation xml:lang="en">Durante C. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy, 2006, doi: https://doi.org/10.1210/jc.2005-2838</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wang R, et al. Analysis of radioiodine therapy and prognostic factors for pulmonary metastases from papillary thyroid carcinoma, 2017, doi: https://doi.org/10.3892/ol.2017.6196</mixed-citation><mixed-citation xml:lang="en">Wang R, et al. Analysis of radioiodine therapy and prognostic factors for pulmonary metastases from papillary thyroid carcinoma, 2017, doi: https://doi.org/10.3892/ol.2017.6196</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Giovanella L, et al. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach, 2020, doi: https://doi.org/10.1007/s12020-020-02254-w</mixed-citation><mixed-citation xml:lang="en">Giovanella L, et al. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach, 2020, doi: https://doi.org/10.1007/s12020-020-02254-w</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao H, et al. Prognostic Factors for Survival in Patients With Pulmonary Metastases From Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis, 2020. doi: https://doi.org/10.3389/fonc.2022.990154</mixed-citation><mixed-citation xml:lang="en">Zhao H, et al. Prognostic Factors for Survival in Patients With Pulmonary Metastases From Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis, 2020. doi: https://doi.org/10.3389/fonc.2022.990154</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rothenberg SM, et al. Redifferentiation of iodine-refractory BRAF V600E–mutant metastatic papillary thyroid cancer with dabrafenib, 2015, doi: https://doi.org/10.1158/1078-0432.CCR-14-2915</mixed-citation><mixed-citation xml:lang="en">Rothenberg SM, et al. Redifferentiation of iodine-refractory BRAF V600E–mutant metastatic papillary thyroid cancer with dabrafenib, 2015, doi: https://doi.org/10.1158/1078-0432.CCR-14-2915</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Weber M, et al. Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): A single-center prospective two-arm study, 2020. doi: https://doi.org/10.1158/1078-0432.CCR-22-0437</mixed-citation><mixed-citation xml:lang="en">Weber M, et al. Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): A single-center prospective two-arm study, 2020. doi: https://doi.org/10.1158/1078-0432.CCR-22-0437</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zwanenburg A. et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping, 2020. doi: https://doi.org/10.1158/1078-0432.CCR-22-0437</mixed-citation><mixed-citation xml:lang="en">Zwanenburg A. et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping, 2020. doi: https://doi.org/10.1158/1078-0432.CCR-22-0437</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Патент № 2743275 Российская Федерация, МПК А61В 5/00 (2006.01). Способ оценки риска рецидива дифференцированного рака щитовидной железы после проведения радиойодтерапии: №2020128431: опубликовано 16.02.2021 / Бубнов А.А., Трухин А.А., Румянцев П.О., Дегтярев М.В., Серженко С.С., Слащук К.Ю., Колпакова Е.А., Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А.</mixed-citation><mixed-citation xml:lang="en">Patent № 2743275 Rossijskaya Federaciya, MPK A61V 5/00 (2006.01). Sposob ocenki riska recidiva differencirovannogo raka shchitovidnoj zhelezy posle provedeniya radiojodterapii: №2020128431: opublikovano 16.02.2021 / Bubnov A.A., Truhin A.A., Rumyancev P.O., Degtyarev M.V., Serzhenko S.S., Slashchuk K.YU., Kolpakova E.A., Dedov I.I., Mokrysheva N.G., Mel’nichenko G.A.]</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
